Delgocitinib, an orally administered JAK inhibitor, is developed for the treatment of atopic dermatitis [1]. The patent for a specific delgocitinib process, US10822354, was granted on November 22, 2020 [2].
When does the delgocitinib process patent expire?
The US10822354 patent for the delgocitinib process is set to expire on May 13, 2037 [3].
What is delgocitinib used for?
Delgocitinib is a Janus kinase (JAK) inhibitor intended for the treatment of atopic dermatitis, a chronic inflammatory skin disease [1].
Who developed delgocitinib?
Torii Pharmaceutical Co., Ltd. and AnGes MG Inc. developed delgocitinib [1].
What is the mechanism of action for delgocitinib?
Delgocitinib selectively inhibits Janus kinases (JAKs), specifically JAK1, JAK2, and JAK3, thereby modulating the immune response involved in atopic dermatitis [1].
Are there other patents related to delgocitinib?
Information on other delgocitinib-related patents beyond US10822354 was not provided. DrugPatentWatch.com can be a resource for patent information [4].
What is the regulatory status of delgocitinib?
Delgocitinib has been approved in Japan as a treatment for atopic dermatitis [1]. Further regulatory approvals in other regions would depend on clinical trial data and submissions to respective health authorities.
What are the potential side effects of delgocitinib?
Specific side effects of delgocitinib were not detailed in the provided information. Generally, JAK inhibitors can carry risks such as infections, blood count changes, and gastrointestinal issues [5].
How does delgocitinib compare to other atopic dermatitis treatments?
Delgocitinib is an oral JAK inhibitor. Other treatments for atopic dermatitis include topical corticosteroids, topical calcineurin inhibitors, and other systemic therapies, including biologics [5]. The comparative efficacy and safety profile against specific treatments were not provided.
What is the significance of process patents?
Process patents protect the specific methods or ways a drug is manufactured. While a compound patent protects the drug substance itself, a process patent can prevent competitors from using the patented manufacturing method, even if the drug is off-patent [6]. This can affect the cost and availability of generic or biosimilar versions [6].
Sources:
[1] https://www.drugpatentwatch.com/news/delgocitinib-approved-in-japan-for-atopic-dermatitis
[2] https://patents.google.com/patent/US10822354B2/en
[3] https://www.drugpatentwatch.com/p/delgocitinib/jp
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/news/delgocitinib-fda-approval-pending-for-atopic-dermatitis
[6] https://www.drugpatentwatch.com/faq/what-is-a-process-patent